Mechanisms of Local Immunoresistance in Glioma

被引:58
作者
Albesiano, Emilia [2 ]
Han, James E. [1 ]
Lim, Michael [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Sch Med, Dept Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA
关键词
Glioblastoma multiforme; Immunotherapy; Oncogenic signaling pathway; Immunoresistance; ENDOTHELIAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; PRIMARY INTRACRANIAL TUMORS; FAS LIGAND EXPRESSION; REGULATORY T-CELLS; HUMAN GLIOBLASTOMA CELLS; CONFER IMMUNE PRIVILEGE; PERIPHERAL-BLOOD; IN-VIVO; INDOLEAMINE 2,3-DIOXYGENASE;
D O I
10.1016/j.nec.2009.08.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Even though the central nervous system (CNS) was conventionally defined as "immunologically privileged", new discoveries have demonstrated the role of the immune system in neurologic disease and illness, including gliomas. Brain tumor immunotherapy is an exciting and revived area of research, in which neurosurgeons have taken a major position. Despite the ability to induce a tumor-specific systemic immune response, the challenge to effectively eradicate intracranial gliomas remains mainly because of tumor-induced immunoresistance. This article gives an overview of the immunologic responses that occur in the CNS and their potential role in brain tumors. The main cellular and molecular mechanisms that mediate tumor escape from natural immune surveillance are also covered in this article. Glioma cells have been shown to diminish the expression of danger signals necessary for immune activation and to increase the concentration of immunosuppressive factors in the tumor microenvironment, which results in T-cell anergy or apoptosis. Finally, the authors discuss most of the over-expressed oncogenic signaling pathways that cause tumor tolerance.
引用
收藏
页码:17 / +
页数:14
相关论文
共 163 条
[11]  
2-G
[12]   The role of STATs in transcriptional control and their impact on cellular function [J].
Bromberg, J ;
Darnell, JE .
ONCOGENE, 2000, 19 (21) :2468-2473
[13]   Stat proteins and oncogenesis [J].
Bromberg, J .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (09) :1139-1142
[14]   Tumor-induced immune dysfunctions caused by myeloid suppressor cells [J].
Bronte, V ;
Serafini, P ;
Apolloni, E ;
Zanovello, P .
JOURNAL OF IMMUNOTHERAPY, 2001, 24 (06) :431-446
[15]   DEPRESSED CELL-MEDIATED IMMUNITY IN PATIENTS WITH PRIMARY INTRACRANIAL TUMORS - CHARACTERIZATION OF A HUMORAL IMMUNOSUPPRESSIVE FACTOR [J].
BROOKS, WH ;
NETSKY, MG ;
NORMANSELL, DE ;
HORWITZ, DA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1972, 136 (06) :1631-+
[16]  
Buckner JC, 2001, CANCER-AM CANCER SOC, V92, P420, DOI 10.1002/1097-0142(20010715)92:2<420::AID-CNCR1338>3.0.CO
[17]  
2-3
[18]   Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses [J].
Butte, Manish J. ;
Keir, Mary E. ;
Phamduy, Theresa B. ;
Sharpe, Arlene H. ;
Freeman, Gordon J. .
IMMUNITY, 2007, 27 (01) :111-122
[19]   Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation [J].
Câmara, NOS ;
Sebille, F ;
Lechler, RI .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (12) :3473-3483
[20]   Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases [J].
Camby, I ;
Belot, N ;
Lefranc, F ;
Sadeghi, N ;
de Launoit, Y ;
Kaltner, H ;
Musette, S ;
Darro, F ;
Danguy, A ;
Salmon, I ;
Gabius, HJ ;
Kiss, R .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2002, 61 (07) :585-596